Related Experiment Video
Updated: Jun 11, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Special lectures in haemophilia management
A Batorova1, K A High, A Gringeri
1Department of Haematology and Blood Transfusion Medicine, University Hospital, National Haemophilia Centre, Bratislava, Slovakia. batorova@hotmail.sk
Summary
Advances in hemophilia management focus on preventing bleeds. Future treatments aim for longer efficacy and reduced immunogenicity, with gene therapy offering a potential cure for hemophilia.
Area of Science:
- Hematology
- Immunology
- Gene Therapy
Background:
- Significant progress in hemophilia management has been made over the past two decades.
- Current treatments focus on preventing recurrent bleeding episodes and their complications.
- Challenges include short therapeutic half-lives, frequent injections, and the risk of inhibitor development.
Purpose of the Study:
- To discuss advancements in hemophilia management.
- To explore challenges in current treatment regimens.
- To highlight ongoing research in gene therapy and inhibitor development.
Main Methods:
- Review of modern approaches in hemophilia management.
- Discussion of gene therapy research for factor VIII (FVIII) and factor IX (FIX) production.
- Analysis of immunogenicity of plasma-derived FVIII (pdFVIII) and recombinant FVIII (rFVIII) concentrates.
Main Results:
- Intensive research is ongoing for gene therapy to cure hemophilia.
- Mechanisms of immune response modification to FVIII and FIX are under investigation.
- The SIPPET study aims to determine inhibitor incidence in patients treated with pdFVIII versus rFVIII.
Conclusions:
- Further development is needed for factor concentrates with prolonged efficacy and reduced immunogenicity.
- Gene therapy holds promise for the ultimate cure of hemophilia.
- Understanding and mitigating inhibitor development remains a critical challenge in hemophilia therapy.
Related Concept Videos
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:05Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...